B. Riley says Nektar’s (NKTR) litigation pre-trial hearing against Eli Lilly (LLY) has been delayed from October 16 until at least until after December 11 due to the government shutdown. Nektar’s catalyst path is now more focused on continued Rezpeg “de-risking” Phase 2 data generation activities, the analyst tells investors in a research note. The firm believes the “wide variance of investor expectations” on the Lilly litigation outcomes is likely to narrow as a result of additional Phase 2 clinical data accumulation. Riley reiterates a Buy rating on Nektar with a $105 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Nektar price target raised to $99 from $69 at Jefferies
- Nektar Therapeutics Reveals Promising Phase 2b Study Results
- Nektar’s rezpegaldesleukin shows efficacy in Phase 2b atopic dermatitis trial
- Nektar management to meet with Piper Sandler
- Sanofi’s ‘disappointing’ atopic dermatitis data sends Nektar higher